Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "to BCMA CAR-T cell therapy co-developed by Innoven"

Orphan Drug Designation offered by US FDA to BCMA CAR-T cell therapy co-developed by Innovent Biologics and IASO Bio

The US Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) has formally granted Orphan Drug Designation (ODD) to Innovent Biologics's fully-human B-Cell Maturation Antigen (BCMA)-targetted Chimeric Antigen Receptor (CAR) T-cell therapy

To BCMA CAR-T Cell Therapy Co-developed By Innoven | 17/02/2022 | By Darshana | 637

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members